ID

15976

Description

Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT02082405

Link

https://clinicaltrials.gov/show/NCT02082405

Keywords

Versions (1)
  1. 6/22/16 6/22/16 -
Uploaded on

June 22, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Stage I Multiple Myeloma NCT02082405

English

Eligibility Stage I Multiple Myeloma NCT02082405

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must have a confirmed diagnosis of symptomatic myeloma in accordance with international myeloma working group (imwg) criteria
Description

Multiple Myeloma Symptomatic

Data type

boolean

Alias
UMLS CUI [1,1]
C0026764
UMLS CUI [1,2]
C0231220
bone marrow plasmacytosis with > 10% plasma cells or sheets of plasma cells or biopsy proven plasmacytoma
Description

BONE MARROW PLASMACYTOSIS | Plasma Cells | Plasmacytoma | Biopsy

Data type

boolean

Alias
UMLS CUI [1]
C0238803
UMLS CUI [2]
C0032112
UMLS CUI [3]
C0032131
UMLS CUI [4]
C0005558
symptomatic disease, i.e., end-organ damage due to multiple myeloma (mm) including at least one of the following: anemia, hypercalcemia, bone disease (lytic bone lesions or pathologic fracture), or renal dysfunction
Description

Disease Symptomatic | end organ damage Due to Multiple Myeloma | Anemia | Hypercalcemia | Bone Diseases | Lytic lesion | Pathological fracture | Renal dysfunction

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0231220
UMLS CUI [2,1]
C0743496
UMLS CUI [2,2]
C0678226
UMLS CUI [2,3]
C0026764
UMLS CUI [3]
C0002871
UMLS CUI [4]
C0020437
UMLS CUI [5]
C0005940
UMLS CUI [6]
C0221204
UMLS CUI [7]
C0016663
UMLS CUI [8]
C3279454
absolute neutrophil count (anc) >= 1000 cells/mm^3 (without use of growth factors)
Description

Absolute neutrophil count

Data type

boolean

Alias
UMLS CUI [1]
C0948762
platelets >= 50,000 cells/mm^3
Description

Platelet Count measurement

Data type

boolean

Alias
UMLS CUI [1]
C0032181
direct bilirubin =< 1.5 x upper limit of normal (uln); elevated bilirubin is permissible if patient has a known history of elevated bilirubin due to gilbert's or if elevated bilirubin is due to hemolysis
Description

Bilirubin, direct measurement | Increased bilirubin level Due to Gilbert Disease | Increased bilirubin level Due to Hemolysis

Data type

boolean

Alias
UMLS CUI [1]
C0201916
UMLS CUI [2,1]
C0311468
UMLS CUI [2,2]
C0678226
UMLS CUI [2,3]
C0017551
UMLS CUI [3,1]
C0311468
UMLS CUI [3,2]
C0678226
UMLS CUI [3,3]
C0019054
alanine aminotransferase (alt) (serum glutamate pyruvate transaminase [sgpt]) =< 1.5 x uln
Description

Alanine aminotransferase measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201836
subjects must have the ability to understand and the willingness to sign a written informed consent document
Description

Informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with > 1 cycle of any plasma cell myeloma (pcm) induction regimen (maximum 6 weeks of prior treatment)
Description

Prior Therapy | Multiple Myeloma Neoadjuvant Therapy

Data type

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2,1]
C0026764
UMLS CUI [2,2]
C0600558
prior radiation therapy is allowed
Description

prior radiation therapy

Data type

boolean

Alias
UMLS CUI [1]
C0279134
prior treatment for other cancers is allowed as long as patient meets criteria for adequate hematopoietic and organ function and is not actively on chemotherapy for another cancer
Description

Prior Therapy Malignant Neoplasms Other | physiological aspects Hematopoietic | organ function | Chemotherapy Malignant Neoplasm Other

Data type

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0006826
UMLS CUI [1,3]
C0205394
UMLS CUI [2,1]
C0031843
UMLS CUI [2,2]
C0229601
UMLS CUI [3]
C0678852
UMLS CUI [4,1]
C3665472
UMLS CUI [4,2]
C0006826
UMLS CUI [4,3]
C0205394
grade >= 2 peripheral neuropathy
Description

Peripheral Neuropathy

Data type

boolean

Alias
UMLS CUI [1]
C0031117
second malignancy currently undergoing chemotherapy or radiotherapy; hormonal therapy for breast or prostate cancer is allowed
Description

Neoplasms, Second Primary | Chemotherapy | Therapeutic radiology procedure | Hormone Therapy Breast Carcinoma | Hormone Therapy Prostate carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0085183
UMLS CUI [2]
C0392920
UMLS CUI [3]
C1522449
UMLS CUI [4,1]
C0279025
UMLS CUI [4,2]
C0678222
UMLS CUI [5,1]
C0279025
UMLS CUI [5,2]
C0600139
patients may not be receiving any other investigational agents
Description

Investigational New Drugs Other

Data type

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C0205394
history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib, cyclophosphamide, dexamethasone or other agents used in this study
Description

Allergic Reaction bortezomib | Allergic Reaction Cyclophosphamide | Allergic Reaction Dexamethasone | Allergic Reaction Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1,1]
C1527304
UMLS CUI [1,2]
C1176309
UMLS CUI [2,1]
C1527304
UMLS CUI [2,2]
C0010583
UMLS CUI [3,1]
C1527304
UMLS CUI [3,2]
C0011777
UMLS CUI [4,1]
C1527304
UMLS CUI [4,2]
C0013230
patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Description

Comorbidity Compliance behavior Limited | Communicable Diseases | Symptomatic congestive heart failure | Angina, Unstable | Cardiac Arrhythmia | Mental disorders | social situation

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C1321605
UMLS CUI [1,3]
C0439801
UMLS CUI [2]
C0009450
UMLS CUI [3]
C0742758
UMLS CUI [4]
C0002965
UMLS CUI [5]
C0003811
UMLS CUI [6]
C0004936
UMLS CUI [7]
C0748872
Back to the top of the page

Similar models

Eligibility Stage I Multiple Myeloma NCT02082405

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Multiple Myeloma Symptomatic
Item
patients must have a confirmed diagnosis of symptomatic myeloma in accordance with international myeloma working group (imwg) criteria
boolean
C0026764 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
BONE MARROW PLASMACYTOSIS | Plasma Cells | Plasmacytoma | Biopsy
Item
bone marrow plasmacytosis with > 10% plasma cells or sheets of plasma cells or biopsy proven plasmacytoma
boolean
C0238803 (UMLS CUI [1])
C0032112 (UMLS CUI [2])
C0032131 (UMLS CUI [3])
C0005558 (UMLS CUI [4])
Disease Symptomatic | end organ damage Due to Multiple Myeloma | Anemia | Hypercalcemia | Bone Diseases | Lytic lesion | Pathological fracture | Renal dysfunction
Item
symptomatic disease, i.e., end-organ damage due to multiple myeloma (mm) including at least one of the following: anemia, hypercalcemia, bone disease (lytic bone lesions or pathologic fracture), or renal dysfunction
boolean
C0012634 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0743496 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0026764 (UMLS CUI [2,3])
C0002871 (UMLS CUI [3])
C0020437 (UMLS CUI [4])
C0005940 (UMLS CUI [5])
C0221204 (UMLS CUI [6])
C0016663 (UMLS CUI [7])
C3279454 (UMLS CUI [8])
Absolute neutrophil count
Item
absolute neutrophil count (anc) >= 1000 cells/mm^3 (without use of growth factors)
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelets >= 50,000 cells/mm^3
boolean
C0032181 (UMLS CUI [1])
Bilirubin, direct measurement | Increased bilirubin level Due to Gilbert Disease | Increased bilirubin level Due to Hemolysis
Item
direct bilirubin =< 1.5 x upper limit of normal (uln); elevated bilirubin is permissible if patient has a known history of elevated bilirubin due to gilbert's or if elevated bilirubin is due to hemolysis
boolean
C0201916 (UMLS CUI [1])
C0311468 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0017551 (UMLS CUI [2,3])
C0311468 (UMLS CUI [3,1])
C0678226 (UMLS CUI [3,2])
C0019054 (UMLS CUI [3,3])
Alanine aminotransferase measurement
Item
alanine aminotransferase (alt) (serum glutamate pyruvate transaminase [sgpt]) =< 1.5 x uln
boolean
C0201836 (UMLS CUI [1])
Informed consent
Item
subjects must have the ability to understand and the willingness to sign a written informed consent document
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Prior Therapy | Multiple Myeloma Neoadjuvant Therapy
Item
prior treatment with > 1 cycle of any plasma cell myeloma (pcm) induction regimen (maximum 6 weeks of prior treatment)
boolean
C1514463 (UMLS CUI [1])
C0026764 (UMLS CUI [2,1])
C0600558 (UMLS CUI [2,2])
prior radiation therapy
Item
prior radiation therapy is allowed
boolean
C0279134 (UMLS CUI [1])
Prior Therapy Malignant Neoplasms Other | physiological aspects Hematopoietic | organ function | Chemotherapy Malignant Neoplasm Other
Item
prior treatment for other cancers is allowed as long as patient meets criteria for adequate hematopoietic and organ function and is not actively on chemotherapy for another cancer
boolean
C1514463 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0031843 (UMLS CUI [2,1])
C0229601 (UMLS CUI [2,2])
C0678852 (UMLS CUI [3])
C3665472 (UMLS CUI [4,1])
C0006826 (UMLS CUI [4,2])
C0205394 (UMLS CUI [4,3])
Peripheral Neuropathy
Item
grade >= 2 peripheral neuropathy
boolean
C0031117 (UMLS CUI [1])
Neoplasms, Second Primary | Chemotherapy | Therapeutic radiology procedure | Hormone Therapy Breast Carcinoma | Hormone Therapy Prostate carcinoma
Item
second malignancy currently undergoing chemotherapy or radiotherapy; hormonal therapy for breast or prostate cancer is allowed
boolean
C0085183 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C0279025 (UMLS CUI [4,1])
C0678222 (UMLS CUI [4,2])
C0279025 (UMLS CUI [5,1])
C0600139 (UMLS CUI [5,2])
Investigational New Drugs Other
Item
patients may not be receiving any other investigational agents
boolean
C0013230 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Allergic Reaction bortezomib | Allergic Reaction Cyclophosphamide | Allergic Reaction Dexamethasone | Allergic Reaction Investigational New Drugs
Item
history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib, cyclophosphamide, dexamethasone or other agents used in this study
boolean
C1527304 (UMLS CUI [1,1])
C1176309 (UMLS CUI [1,2])
C1527304 (UMLS CUI [2,1])
C0010583 (UMLS CUI [2,2])
C1527304 (UMLS CUI [3,1])
C0011777 (UMLS CUI [3,2])
C1527304 (UMLS CUI [4,1])
C0013230 (UMLS CUI [4,2])
Comorbidity Compliance behavior Limited | Communicable Diseases | Symptomatic congestive heart failure | Angina, Unstable | Cardiac Arrhythmia | Mental disorders | social situation
Item
patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
boolean
C0009488 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,3])
C0009450 (UMLS CUI [2])
C0742758 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0003811 (UMLS CUI [5])
C0004936 (UMLS CUI [6])
C0748872 (UMLS CUI [7])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial